Necrotizing autoimmune myopathy (NAM) is an emerging cause of severe statin-induced myopathy, treatable with immunosuppression, believed to result from autoantibodies (aAb) against 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the enzyme target of statins. Here the authors describe the development of an addressable laser bead immunoassay (ALBIA) to identify patients with NAM, and subsequent incorporation into a multiplex format with a previously described assay for a similar necrotizing myopathy, unrelated to statins, owing to signal recognition peptide (SRP) aAbs.
A total of 37% of 150 patients suspected to have NAM were found to have detectable anti-HMGCR aAbs, and a cutoff of 20 arbitrary units per litre had 100% sensitivity and specificity for differentiating these patients from healthy controls, as well as from patients with other autoimmune diseases. The multiplex format was able to perfectly discriminate anti-HMGCR from anti-SRP positive sera. Of note, 60% of anti-HMGCR positive patients had no prior statin exposure.
This article should raise awareness of autoimmune myopathy in statin-treated patients. It is noteworthy however, that 60% with anti-HMGCR aAbs had never received statins, as this condition was thought to be very rare in statin-naı¨ve individuals. Immunoglobulin G4-related disease (IgG4-RD) is a chronic fibroinflammatory condition frequently associated with IgG4-positive plasma cell infiltration and increased circulating IgG4. This study assessed the diagnostic utility of serum IgG4 measurement in 6014 patients with a variety of presentations who had IgG4 measured using a latex-enhanced nephelometric immunoassay. Only patients with IgG4 above the upper limit of normal (ULN) (390 patients) were included in analysis.
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Of the 390 cases of raised IgG4, only 10% had definite or probable IgG4-RD. The majority of these (25/39) had autoimmune pancreatitis. Although a higher proportion of patients with definite or probable IgG4-RD had significantly raised (2 Â ULN) IgG4 (P < 0.05), a receiver operating characteristic curve area under curve of 0.64 and a poor positive predictive value (10%) of a raised IgG4 were both noted.
The study highlights the spectrum of IgG4-related disease, but found elevated IgG4 was a poor predictor of IgG4-RD in an institution-wide cohort. Limitations include retrospective design, reliance on judgement of different clinicians for diagnoses, lack of reasons for measurement of IgG4, and possible misclassification of IgG4-RD with non-classical presentations. Also, the study does not address the use of IgG4 in selected patients with a high probability of IgG4-RD, when the test is likely to be of more value. 
Laura Hewitt

